Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for ...